Want to see NUTX full AI Analyst Report?
NUTX Stock Chart & Stats
$145.87
-$7.69(-5.01%)
At close: 4:00 PM EDT
$145.87
-$7.69(-5.01%)
Day’s Range― - ―
52-Week Range$77.21 - $204.00
Previous Close$145.87
Volume132.68K
Average Volume (3M)120.76K
Market Cap
$966.76M
Enterprise Value$916.51
Total Cash (Recent Filing)$207.35M
Total Debt (Recent Filing)$349.09M
Price to Earnings (P/E)11.1
Beta2.44
Next Earnings
Aug 06, 2026EPS Estimate
4.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.44
Shares Outstanding6,881,339
10 Day Avg. Volume109,184
30 Day Avg. Volume120,759
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$233.33Price Target Upside59.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)21.52
Revenue Forecast (FY)$880.37M
Bulls Say, Bears Say
Bulls Say
Strong Operating Cash Flow And Free Cash FlowSustained high operating and free cash flow provides durable internal funding for hospital development, buybacks, and deleveraging. Strong FCF versus net income suggests high earnings quality and lowers reliance on external financing over the next 2–6 months.
Material Deleveraging And Stronger Capital BaseMeaningful reduction in leverage increases financial flexibility, lowers interest burden and improves resilience to reimbursement swings. A stronger balance sheet supports planned internal hospital builds and sale-leaseback monetization without stressing liquidity.
Structural Reduction In Arbitration/IDR CostsContract and regulatory changes materially lower arbitration-related fees and change cost timing. This structurally improves unit economics for dispute resolution, reduces margin volatility from IDR timing, and increases predictable net recoveries over coming quarters.
Bears Say
Significant Gross Margin CompressionA large, recent decline in gross margin reflects higher facility operating and arbitration costs and weaker unit economics. If labor, supply, or arbitration pressures persist, margin recovery will be constrained, limiting sustainable return on invested capital.
Rising Accounts Receivable Elevates Working Capital NeedsGrowing receivables, tied to IDR timing and collections, tie up cash and increase financing risk. Persistently higher AR can erode free cash flow conversion and force slower expansion or more external funding during periods of tighter reimbursement timing.
Historical Profitability And Cash Conversion VolatilityPrior multi-year losses and inconsistent cash conversion show operational sensitivity to reimbursement and timing effects. Even after a turnaround, the company remains exposed to cyclical or regulatory shocks that could quickly reverse improvements.
Clinigence Holdings News
NUTX FAQ
What was Clinigence Holdings Inc’s price range in the past 12 months?
Clinigence Holdings Inc lowest stock price was $77.21 and its highest was $204.00 in the past 12 months.
What is Clinigence Holdings Inc’s market cap?
Clinigence Holdings Inc’s market cap is $966.76M.
When is Clinigence Holdings Inc’s upcoming earnings report date?
Clinigence Holdings Inc’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were Clinigence Holdings Inc’s earnings last quarter?
Clinigence Holdings Inc released its earnings results on Apr 30, 2026. The company reported $6.52 earnings per share for the quarter, beating the consensus estimate of $3.993 by $2.527.
Is Clinigence Holdings Inc overvalued?
According to Wall Street analysts Clinigence Holdings Inc’s price is currently Undervalued.
Does Clinigence Holdings Inc pay dividends?
Clinigence Holdings Inc does not currently pay dividends.
What is Clinigence Holdings Inc’s EPS estimate?
Clinigence Holdings Inc’s EPS estimate is 4.95.
How many shares outstanding does Clinigence Holdings Inc have?
Clinigence Holdings Inc has 6,881,339 shares outstanding.
What happened to Clinigence Holdings Inc’s price movement after its last earnings report?
Clinigence Holdings Inc reported an EPS of $6.52 in its last earnings report, beating expectations of $3.993. Following the earnings report the stock price went up 17.089%.
Which hedge fund is a major shareholder of Clinigence Holdings Inc?
Currently, no hedge funds are holding shares in NUTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$233.33 (59.96% Upside)
$233.33 (59.96% Upside)
Blogger Sentiment
Neutral
NUTX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.65%
Trailing 12-Months
Company Description
Clinigence Holdings Inc
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
NUTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: operationally and strategically Nutex demonstrates strong liquidity, improved net income, positive cash flow, active share repurchases, patient satisfaction, and a clear strategy to internalize development and scale population health. However, significant margin pressure and a 21% drop in adjusted EBITDA driven by higher facility costs and timing effects from IDR/arbitration recognition temper the results. Same-hospital revenue growth was minimal and accounts receivable rose, highlighting near-term execution and working capital considerations. Regulatory and arbitration accounting dynamics introduce additional volatility. Overall, positive cash generation and strategic initiatives are balanced by meaningful margin and accounting headwinds.View all NUTX earnings summariesNUTX Stock 12 Month Forecast
Average Price Target
$233.33
▲(59.96% Upside)
Technical Analysis
AMN Healthcare Services
―
Pennant Group
―
InnovAge Holding
―
Agilon Health
―
Ardent Health Partners, Inc.
―
Ownership Overview
32.86% Insiders
6.87% Mutual Funds
0.69% Other Institutional Investors
45.65% Public Companies and
Individual Investors